Nancy Hanson

Learn More
We reviewed all Mayo Clinic case histories in which a diagnosis of tardive dyskinesia or dyskinesia might have been recorded during the years 1965 through 1973 and interviewed 18 consecutive patients in the Department of Psychiatry and Psychology. Among the histories and patients, we found a high incidence of primary affective disorders. Four of the five (More)
Patients with odor-triggered symptoms, meeting the case definition of multiple chemical sensitivities (MCS), continue to be seen in our institution and other health science centers [Amundsen, Mayo Clinic Dept. Intern. Med. Newslett. 9(1) (1986)]. The term MCS, unfortunately, feeds the thesis that symptoms are allergic-immune system in origin, a theory that(More)
1. Adamec, R. 1994. Modelling anxiety disorders following chemical exposures. Statement on multiple chemical hypersensitivity syndrome, multiple chemical sensitivities, environmental tobacco smoke, and indoor air quality. Odor aversion of multiple chemical sensitivities: recommendation for a name change and description of successful behavioral medicine(More)
BACKGROUND Guidelines recommend genetic counseling and testing for women who have a pedigree suggestive of an inherited susceptibility for ovarian cancer. The authors evaluated the effect of referral to genetic counseling on genetic testing and prophylactic oophorectomy in a randomized controlled trial. METHODS Data from an electronic mammography(More)
AmpC beta-lactamases are not inhibited by clavulanic acid and could potentially mask detection of extended-spectrum beta-lactamases (ESBLs) using the Clinical and Laboratory Standards Institute confirmatory test. Syn2190 (1,5-dihydroxy-4-pyridone monobactam) selectively inhibits AmpC, but not ESBLs. Fifty-four MicroScan ESBL screen-positive strains of(More)
OBJECTIVE We sought to determine whether prophylactic oophorectomy rates changed after the introduction of a 2007 health plan clinical guideline recommending systematic referral to a genetic counselor for women with a personal or family history suggestive of an inherited susceptibility to breast/ovarian cancer. METHODS We conducted a retrospective cohort(More)
Women with a documented deleterious mutation in BRCA1 or BRCA2 are at substantially elevated risk for ovarian cancer. To understand what percentage of women with high-risk family histories know their risk is elevated we surveyed 1,885 women with a high- or moderate-risk family history and no personal history of breast or ovarian cancer, and asked about(More)